Communiqués InnoCan Pharma Corporation

Actions

INNO

CA45783P1027

Marché Fermé - Canadian Securities Exchange Autres places de cotation 17:58:51 27/06/2024			Varia. 5j.	Varia. 1 janv.
0,25 ^CAD	0,00 %		-3,85 %	-19,35 %

27/05	InnoCan Pharma Corporation annonce ses résultats pour le premier trimestre terminé le 31 mars 2024	CI
27/05	Innocan Pharma annonce ses résultats pour le premier trimestre 2024 avec une croissance des revenus de plus de 4 fois pour atteindre 6,8 millions de dollars	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs	11/06	AQ
Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million	27/05	AQ
FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain	21/05	AQ
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey	09/05	AQ
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain	22/04	AQ
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M	01/04	AQ
Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.	25/03	AQ
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million	15/03	AQ
Innocan Pharma's LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study	05/03	AQ
Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits	26/02	AQ
Innocan Pharma to participate in the White Label World Expo on February 27-28th, 2024	20/02	AQ
Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights	13/02	AQ
Innocan Pharma to provide a corporate update via Zoom livestream on February 12, 2024, at 4:00pm EST	05/02	AQ
Innocan Pharma Announces Expert Team for LPT CBD Application to United States Food and Drug Administration	12/12	AQ
Innocan Pharma Reports Q3 2023 Results Including US$3.334M Increase in Revenues Compared to Q3, 2022	29/11	AQ
Innocan Pharma Announces Promising LPT-CBD Safety Indications -Implications from a prolong use in animals	03/11	AQ
Innocan Pharma reports a groundbreaking discovery regarding its LPD platform and global CBD research	23/10/23	AQ
Innocan Pharma Announces Closing of Second and Final Tranche of Financing	20/10/23	AQ
Innocan Pharma Announces Closing of First Tranche Private Placement and Provides Corporate Update	12/10/23	AQ
Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million	21/09/23	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués InnoCan Pharma Corporation

Actions

INNO

CA45783P1027

Communiqués

Filtres